# US 9,872,910 B2 · Aqueous ophthalmic composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,872,910 B2
- Document ID: US9872910B2
- Status: Granted
- Kind: B2
- Application number: 15/399,757
- Filed: 2017-01-06
- Published: 2017-04-27
- Granted: 2018-01-23
- Earliest claimed: 2014-07-11
- Assignees: FUJIFILM Corporation
- Applicants: Fujifilm Corporation
- Inventors: Shirou Sonoke; Yasuyuki Izumi; Shigetomo Tsujihata
- Web page: https://patentgrep.com/patent/US9872910B2

## CPC

- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An aqueous ophthalmic composition includes a carbonic anhydrase inhibitor; at least one cellulose derivative selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate and carboxymethylethyl cellulose; and water.

## Claims

### Claim 1

An aqueous ophthalmic composition comprising:
a carbonic anhydrase inhibitor;
a cellulose derivative comprising hydroxypropylmethyl cellulose acetate succinate;
another cellulose derivative comprising hydroxypropylmethyl cellulose; and
water.

### Claim 2 (depends on 1)

The aqueous ophthalmic composition according to claim 1, wherein a content of the carbonic anhydrase inhibitor with respect to the total mass of the aqueous ophthalmic composition is from 0.1% by mass to 10% by mass.

### Claim 3 (depends on 1)

The aqueous ophthalmic composition according to claim 1, wherein a total content of the cellulose derivative with respect to the total mass of the aqueous ophthalmic composition is from 0.05% by mass to 5% by mass.

### Claim 4 (depends on 1)

The aqueous ophthalmic composition according to claim 1, wherein the carbonic anhydrase inhibitor is brinzolamide.

### Claim 5 (depends on 1)

The aqueous ophthalmic composition according to claim 1, wherein a content of the hydroxypropylmethyl cellulose with respect to the total mass of the aqueous ophthalmic composition is from 0.05% by mass to 5% by mass.

### Claim 6 (depends on 1)

The aqueous ophthalmic composition according to claim 1, further comprising a carboxyvinyl polymer.

### Claim 7 (depends on 6)

The aqueous ophthalmic composition according to claim 6, wherein a content of the carboxyvinyl polymer with respect to the total mass of the aqueous ophthalmic composition is from 0.1% by mass to 10% by mass.